Sunday, July 3, 2022


SAS and bioMérieux Partnership to Fight Antimicrobial Resistance

Latest Posts

Worldwide Biopharmaceuticals Contract Manufacturing Industry is Expected to Reach $67.9 Billion by 2027

The Global Biopharmaceuticals Contract Manufacturing Market size was estimated at USD 27.99 billion in 2021 and expected to reach USD 32.37 billion in 2022, and is projected to grow at a CAGR 15.92% to reach USD 67.93 billion by 2027.

Global Chromatography Accessories and Consumables Market Analysis Report 2022: Market to Reach $14.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Chromatography Accessories and Consumables market estimated at US$10.1 Billion in the year 2020, is projected to reach a revised size of US$14.7 Billion by 2027, growing at a CAGR of 5.5% over the analysis period 2020-2027.

Lupus Nephritis Market Insight, Epidemiology and Market Forecast 2032

In the coming years, the Lupus Nephritis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

ROME Therapeutics Announces Publication of First Crystal Structure of a Human Endogenous Reverse Transcriptase in PNAS

ROME Therapeutics notes the study reveals first-ever structure of a non-viral endogenous reverse transcriptase. Human endogenous retrovirus-K (HERV-K) RT shows striking similarity to HIV RT. The findings enable structure-based drug discovery for eRTs

SAS and bioMérieux Partnership to Fight Antimicrobial Resistance

bioMérieux Inc., a world leader in in vitro diagnostic solutions for infectious disease, has partnered with global analytics leader SAS to help combat antimicrobial resistance. As professionals from around the world gather to discuss health analytics and technology at the HIMSS annual conference this week, the companies announced the development of a pioneering analytics solution to arm frontline clinicians with real-time health data for better, faster infection treatment.

The new software-as-a-service offering, BIOMÉRIEUX CLARION™, connects the myriad of health care data inside US hospitals and reference laboratories to provide critical insights to battle public health threats. The innovative solution tracks antimicrobial-resistant (AMR) bacteria and quickly produces data dashboards on SAS® Viya® to empower more informed clinical decision-making. The partnership is rooted in the medical community’s ongoing fight against antimicrobial resistance and the goal to activate and support continuous improvement within antimicrobial stewardship programs.

“Health care providers and clinical laboratory scientists rely on real-time, clinical data, not anecdotes, to render optimal decisions,” said John Hurst, PharmD, BCIDP, Senior Director of Antimicrobial Stewardship for the US at bioMérieux. “CLARION, powered by SAS, revolutionizes antimicrobial stewardship and transforms the antibiogram to be automated and dynamic, providing up-to-date information.”

Antibiotic misuse – including over-prescribing and inaccurate prescribing – causes bacteria and fungi to evolve and become resistant to treatment, leading to 2.8 million infections and more than 35,000 deaths annually in the US. Antibiotic usage has increased during the pandemic due to resources deployed away from antimicrobial stewardship and preemptive antibiotic use in COVID-19 patients. To monitor antibiotic effectiveness and infection response, hospitals typically rely on a standard antibiogram, published once a year with only general information about bacterial pathogens. The static and retrospective nature of this standard report increases the risk a prescriber misses current trends in AMR and potentially prescribes an inappropriate antibiotic.

“As diagnostic technologies have evolved over the past 20 years, antimicrobial practices in hospitals have largely remained the same,” said Steve Kearney, PharmD, Medical Director at SAS. “The next-level technology of CLARION takes advantage of the advanced data management, analytics, and data visualization capabilities of SAS Viya to provide the medical community insights that were never possible before.”

The Centers for Disease Control and Prevention recommends all US hospitals develop an antimicrobial stewardship program to help eliminate drug-resistant superbugs and improve patient health outcomes. The CLARION advanced analytics software provides critical lab and clinical data across departments, processes, and vendors, including regional surveillance of multidrug-resistant organisms, customizable alerts for antibiotic utilization and proof points for federally mandated antimicrobial stewardship program performance elements. The solution’s advanced antibiograms personalize antimicrobial therapy decision making for patients with data that is specific to a hospital system – even a particular unit or floor in a hospital – and the unique characteristics of a patient.

“CLARION allows me to go beyond any previous attempts at data collection and presentation and deliver insights that have been locked away in lab, pharmacy and EMR systems,” said Mike Broyles, PharmD, Director of Pharmacy and Laboratory Services at St. Bernards Five Rivers Medical Center in Arkansas. “I can get what I need without giving months of my life to writing special queries and poring through charts. We create antibiograms in three clicks when it previously took three months.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine